An immune active cancer phenotype typified by a T helper 1 (Th-1) immune response has 44 been associated with increased responsiveness to immunotherapy and favorable prognosis 45 in some but not all cancer types. The reason of this differential prognostic connotation remains 46 unknown. Through a multi-modal Pan-cancer analysis among 31 different histologies (9,282 47 patients), we demonstrated that the favorable prognostic connotation conferred by the 48 presence of a Th-1 immune response was abolished in tumors displaying specific tumor-cell 49 intrinsic attributes such as high TGF-ß signaling and low proliferation capacity. This 50 observation was validated in the context of immune-checkpoint inhibition. WNT-ß catenin, 51 barrier molecules, Notch, hedgehog, mismatch repair, telomerase activity, and AMPK 52 signaling were the pathways most coherently associated with an immune silent phenotype 53 together with mutations of driver genes including IDH1/2, FOXA2, HDAC3, PSIP1, MAP3K1, 54 KRAS, NRAS, EGFR, FGFR3, WNT5A, and IRF7. Our findings could be used to prioritize 55 hierarchically relevant targets for combination therapies and to refine stratification algorithms. 56 57 Keywords 58 -Pan-cancer 59 -Immunologic Constant of Rejection 60 -Prognosis 61 -Mutational load 62 -Neoantigen load 63 -Aneuploidy 64 -Tumor intrinsic pathway enrichment 65 -Cancer Immunotherapy phenotypes (Hendrickx et al., 2017). In particular, we reported that transcriptional 104 dysregulation of the MAPK pathways sustained by genetic alterations (i.e., MAP3K1 and 105 MAP2K4 mutations) are enriched in immune silent tumors (Hendrickx et al., 2017). We also 106 observed that the ICR signature refines and improves the prognostic value of conventional 107 prognostic signatures adopted in breast cancer (Bertucci et al., 2018). Here, we propose a 108 systematic analysis of the entire TCGA cohort encompassing 31 different histologies. Using a 109 pan-cancer approach, we identified novel relationships between tumor genetic programs and 110 immune orientation. After having demonstrated differential associations between ICR 111 classification and overall survival across cancer types, we systemically analyzed in which 112 (molecular) contexts ICR has prognostic value and in which ones it does not. Combination of 113 immune orientation with tumor intrinsic attributes that interact with its prognostic significance 114 could refine tumor immunologic classifications. This approach was validated in the context of 115 immune-checkpoint inhibition allowing better predictive precision.
Introduction

67
Evidence of the effects of anti-tumoral immunity on cancer progression has accumulated 68 over the last decades. The identification of tumor immune escape mechanisms, most 69 importantly the characterization of immune checkpoints, led to major advances in 70 immunotherapy. Immune checkpoint inhibitors have dramatically improved clinical outcome Signif. codes: *** <0.001; ** <0.01; * <0.05
193
ICR cluster entered as categorical (factor) variable (factor levels: "ICR High", "ICR Low")
194
Pathologic stage as semi-continuous variable (Stage I = 1; Stage II = 2; Stage III = 3; Stage IV = 4)
195
LGG and GBM were not included, as tumor stage is not available ( High patients (Figure 2A) . More specifically, ICR High samples showed increased expression 
216
We then proceeded to examine which tumor intrinsic attributes correlate with immune 217 phenotype as reflected by ICR gene expression. We performed ssGSEA to identify enrichment 218 of transcripts of common tumor-related pathways (Hendrickx et al., 2017; Lu et al., 2017;  219 Salerno et al., 2016) . Not surprisingly, immune-related pathways including TNFR1 Signaling 220 and immunogenic cell death showed a strong positive correlation with expression of ICR 221 genes ( Figure 2B ). 
230
TCGA cohort (MAPK-up genes) (Hendrickx et al., 2017) , were also inversely correlated with 231 ICR in a significant proportion of cancers (i.e, ACC, THYM, GBM, LGG and TGCT).
233
Characterization of tumor mutational load and aneuploidy in relation to ICR immune 234 phenotypes 235
Next, we aimed to identify genomic attributes related to the ICR immune phenotypes.
236
As previously observed (Thorsson et al., 2018) , mean neoantigen count of each cancer type 237 strongly correlated with mean mutation rate (Supplementary Figure 6A-B) . While mean non-238 silent mutation rate was significantly higher in ICR High tumors for some cancer types, no 239 clear association was observed in most of them. Results for predicted neoantigen load were 240 similar ( Figure 3A-B and Supplementary Figure 6C-D 
245
Similarly, we studied the association between genomic instabilities, or aneuploidy, and
246
ICR. Specifically, we compared the individual tumor aneuploidy scores and the ICR score 247 across cohorts. Aneuploidy score was calculated as in Taylor et al (Taylor et al., 2018) . As
248
has been reported previously, we found a broad negative association between aneuploidy and 249 raw or tumor purity adjusted ICR score (Davoli et al., 2017) ( Figure 3C) 
263
zero coefficients of the trained model were used to identify genes whose mutation are 264 associated with an increase of the ICR and negative non-zero coefficients identify the genes 265 whose mutations are associated to a decrease of the ICR score ( Figure 4A) . The use of 266 tumor-type as covariate tends to limit the effect of the enrichment of mutations in specific 
276
Interestingly MAP3K1 mutations, whose effect on ICR Low has been described in 277 breast cancer (Hendrickx et al., 2017) , were also associated to ICR Low tumors pan-cancer.
278
The top genes of which mutations positively correlate with ICR reflect immune-evasion 279 mechanisms that follow immunologic pressure such as mutations of antigen-presenting 280 machinery transcripts previously described (i.e., B2M, HLA-A, HLA-B, and CASP8)(Rooney 281 et al., 2015) .
282
To better compare the association between specific mutations and ICR groups within 283 individual cancer types, we calculated, for each of the identified genes, the mean ICR score 284 in the mutated group divided by the mean ICR score in the wild type (WT) within each 285 individual cancer type. For most cancer types, the genes with a positive coefficient consistently 286 showed a higher ICR score in mutated samples, supporting their association with an ICR High 287 phenotype (Figure 4B) 
298
( Supplementary Figure 7A-B ).
299
Mutated genes were frequently part of multiple pathways, suggesting impact on 300 various tumor biological systems (Supplementary Figure 8) .
302
Prognostic impact of ICR classification is dependent on the expression of cancer-related 303 pathways 304
Although we observed interesting differences between ICR High and ICR Low immune 305 phenotypes across different cancer types, these do not explain the divergent association 306 between immune phenotype and survival as we observed in ICR-enabled versus ICR-disabled 307 cancer types (Figure 1C-D) . As previously stated, an active immune phenotype has different 308 impacts on survival depending on molecular subtype (for e.g. breast cancer (Miller et al., 309 2016)). To examine tumor intrinsic differences between ICR-enabled and ICR-disabled cancer 310 types, we compared the enrichment of tumor intrinsic pathways between these two groups.
311
Differentially enriched pathways (t-test; FDR <0.05; Supplementary To better clarify this concept, we selected two of the differentially expressed pathways 343 that were of special interest. Firstly, the "Proliferation" signature was used to classify all 344 samples independent of tumor origin in "Proliferation High" and "Proliferation Low" categories, Figure 10) . Interestingly, in the proliferation high group, ICR High was 363 associated with significantly improved survival independent of mutation rate. A similar 364 observation is made for the mutation rate high group, ICR High is associated with better 365 survival independent of proliferation. These finding suggest that mutation rate and enrichment 366 of proliferation-related transcripts provide additive information to define the prognostic value 367 of ICR. Furthermore, in a multivariate Cox proportional hazards model including ICR 368 classification, proliferation enrichment, TGF-ß signaling enrichment, and tumor mutation rate, 369 all parameters remain significant (Supplementary Figure 11) . This implies that ICR, 370 proliferation rate, TGF-ß signaling and tumor mutation rate all have independent prognostic 371 value.
372
We then continued by verifying whether these tumor intrinsic attributes that interact 373 with the prognostic impact of ICR when evaluated pan-cancer, could also translate to of ICR enabling pathways for most cancer types. For samples with a high enrichment of ICR 379 disabling pathways, the HR was indeed lower (Supplementary Figure S12C) .
380
These data confirm an association between the prognostic impact of ICR classification 381 and enrichment of oncogenic pathways in individual cancer types as well as pan-cancer. Of 382 note, these interactions between the prognostic significance of ICR and tumor intrinsic 383 pathways were mostly present in enabled and neutral cancer types. Within disabled cancer 384 types, with the exception of KIRC, similar associations were not found.
386
Predictive value of ICR score in immune checkpoint therapy is dependent on proliferation and 387 TGF-ß signaling
388
To define the clinical relevance of classification of ICR immune phenotypes, in the 389 setting of immune checkpoint treatment, we first evaluated the predictive value of ICR score 390 across multiple public datasets of anti-CTLA4 and anti-PD1 treatment. A significantly 391 increased expression of ICR in responders compared to non-responders was observed across 392 most of the datasets (Figure 7A) (Chen et al., 2016; Hugo et al., 2016; Prat et al., 2017; Riaz 393 et al., 2017; Van Allen et al., 2015) . The conditional activation of the prognostic impact of the 394 ICR was tested in the Van Allen dataset, which was the only one for which survival information 395 was available. Strikingly, in the proliferation high subgroup, ICR score was significantly higher 
445
As we were interested to compare cancer samples with a highly active immune phenotype 446 with those that have not, the cluster with the highest expression of ICR genes was designated 447 as "ICR High", while the cluster with the lowest ICR gene expression was designated "ICR To define the enrichment of specific gene sets, either reflecting immune cell types (Figure 2A) 475 or specific oncogenic pathways (Figure 2B) 
505
The R package "ComplexHeatmap" was used to plot ICR score ratios between 506 mutated versus wild-type groups. For cancer type/ gene combinations with a number of 507 samples of <3 in the mutated group, ratios were not calculated (NA; grey color in plot). A ratio 508 >1 implies that the ICR score is higher in the mutated group compared with WT, while a ratio 509 <1 implies that the ICR score is higher in subset of tumors without mutation. 
513
Briefly, each tumor was scored for the presence of aneuploid chromosome arms after 514 accounting for tumor ploidy. Tumor aneuploidy scores for each cohort were then compared to 515 ICR scores via linear model with and without purity adjustment. Purity adjustment entailed 516 correlating ICR score and tumor purity (as estimated via ABSOLUTE) and using the residuals 517 to evaluate the post-adjustment relationship between ICR score and tumor aneuploidy. In particular we made use of the precomputed aneuploidy scores and ABSOLUTE tumor purity 519 values. Raw ICR and aneuploidy score associations were evaluated by linear model in R via 520 the lm() function for each cohort independently. Adjusted ICR and aneuploidy score 521 associations were evaluated by first modeling ICR score by tumor purity, then taking the ICR 522 score residuals and assessing the association with aneuploidy score via linear model. Cohorts 523 with model p-values below 0.01 for adjusted or unadjusted ICR score and aneuploidy, 524 regardless of the directionality of the association, were included in Figure 3C .
526
Differential GSEA and stratified survival analysis 527 Differential ES analysis between samples of ICR-enabled and those of ICR-disabled cancer 528 types was performed using t-tests, with a cut-off of FDR-adjusted p-value (i.e., q-value) < 0.05
529
( Supplementary Table 2 ). Tumor intrinsic pathways that were differentially enriched between 530 ICR-enabled and disabled cancer types were selected. The heatmap used for visualization of 531 these differences was generated using the adapted heatmap.3 function (source function). For 532 each of these selected pathways, samples were categorized pan-cancer as pathway-High (ES 533 > median ES) or pathway-Low (ES < median ES). Associations between ICR and survival 534 were defined for each pathway "High" and pathway "Low" group separately using the survival 535 analysis methodology as described above. Pathways for which a significant association 536 between ICR and survival was present in one group, but not in the other one, were selected 537 ( Supplementary Table 3 ). Similarly, these pathways were used to categorize samples per 538 individual cancer type in pathway-High (ES > cancer specific median ES) and pathway-Low 539 (ES < cancer specific median ES). Differences between HRs of groups in individual cancer 540 types were calculated and plotted using "ComplexHeatmap" (v1.17.1).
542
Predictive value ICR score in immune checkpoint datasets 543 ICR scores, or the mean expression of ICR genes, were compared between responders and 544 non-responders to immune checkpoint therapy. For the Chen et al dataset, performed on 545 Nanostring platform, scores were calculated using the 17 ICR genes available in the 546 nanostring panel. Difference in mean ICR score between groups was tested using two-side t-547 test (cutoff <0.95) (Fig 7A) . 
551
Dataset van Allen et al, response was defined as patients with clinical response or long-term 552 survival after treatment (Van Allen et al., 2015) . Samples of van Allen dataset were 553 dichotomized based on median ssGSEA of 1) genes of the proliferation metagene and 2) TGF-Medium and Low groups were defined according to ICR score tertiles, to obtain groups of 556 sufficient size. Stratified survival analysis was performed using the same approach as applied 557 to the TCGA data.
559
Discussion
560
Transcriptional signatures used to define the continuum of cancer immune surveillance 561 and the functional orientation of a protective anti-tumor immunity typically reflect common 562 immune processes and include largely overlapping genes (Ayers et al., 2017; Hendrickx et 563 al., 2017; Wang et al., 2008) . We termed this signature as the ICR (Galon et al., 2013; Wang 564 et al., 2008) .
565
In our systematic analysis we showed that, across and within different tumors, the 566 coordinated overexpression of ICR identifies a microenvironment polarized toward a Th-567 1/cytotoxic response, which was then used to define the hot/immune active tumors.
568
In tumor types with medium/high mutational burden, the mutational or neoantigenic 569 load tended to be higher in hot (ICR high) vs cold (ICR low) tumors while this association was 570 not observed within cancer types with overall low mutational burden. By adding granularity to 571 previous observations that described an overall weak correlation between immunologic 572 correlates of anti-tumor immune response and mutational load (Danaher et al., 2018; Ock et 573 al., 2017; Rooney et al., 2015; Spranger et al., 2016; Thorsson et al., 2018) , we demonstrated 574 here that the differences in term of mutational load was especially evident in tumors types 575 known to be constituted by a significant proportion of microsatellite instable cases, such as 576 COAD, STAD and UCEC. It is likely that, in hypermutated tumors, the excess of neoantigens 577 plays a major role in the immune recognition, while, in the other cases, additional mechanisms, 578 such as cell-intrinsic features, play a major role in shaping the anti-tumor immune response 579 (Hendrickx et al., 2017) . Overall, a high mutational/neoantigen load was neither sufficient nor 580 necessary for the displaying of an active immune microenvironment.
581
When the ICR score was intersected with the enrichment of oncogenic signals as 
623
As for somatic mutations, the top ten genes associated with the immune silent 
648
As for genomic instability, tumors with high aneuploidy are associated with decreased 649 ICR score in a major subset of cancer types (Davoli et al., 2017) . This observation is also in 650 agreement with negative association of a chromosome-instable type with an immune 651 signature that predicts response to immunotherapy with MAGE-A3 antigen as well as 652 response to anti-CTLA-4 treatment in melanoma (Ock et al., 2017) . The only exceptions we 653 found were brain tumors LGG and GBM in which a positive association between aneuploidy 654 and ICR score was detected. In LGG tumors, however, ICR scores positively correlate with 655 tumor grade (Supplementary Figure 4) , and it is possible that the observed positive 656 correlation between aneuploidy and ICR is actually driven by the higher genomic instability 657 characterizing the more advanced tumors.
658
To compare cancer types based on the prognostic value of ICR, we categorized them 659 into two groups: one for which ICR High was associated with increased OS and one for which 
